Retraction: Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation (Cancer Res (2007) 67 (5318-5327) DOI: 10.1158/0008-5472.CAN-06-3996);Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation

Cancer Research

Volumn 67, Issue 11, 2007, Pages 5318-5327

  Chen, Chang Shi ^a   Wang, Yu Chieh ^a   Yang, Hsiao Ching ^a   Huang, Po Hsien ^a   Kulp, Samuel K ^a   Yang, Chih Cheng ^a   Lu, Yen Shen ^a   Matsuyama, Shigemi ^d   Chen, Ching Yu ^b,c   Chen, Ching Shih ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; DOCKING PROTEIN; DOUBLE STRANDED DNA; DOXORUBICIN; ETOPOSIDE; GLUTAMINE; HETERODIMER; HISTONE DEACETYLASE INHIBITOR; HISTONE H2AX; KU ANTIGEN; LYSINE; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; SERINE; TRICHOSTATIN A; VORINOSTAT;

ACETYLATION; ARTICLE; BINDING AFFINITY; CANCER CELL; CELL KILLING; CELL VIABILITY; COMPUTER ANALYSIS; CONTROLLED STUDY; DEACETYLATION; DIMERIZATION; DNA BINDING; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; DRUG MECHANISM; DRUG SENSITIZATION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SITE DIRECTED MUTAGENESIS;

EID: 34347206854     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-18-1291     Document Type: Erratum

References (42)

1. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-84.
2. Lin HY, Chen CS, Lin SP, Weng JR, Chen CS. Targeting histone deacetylase in cancer therapy. Med Res Rev 2006;26:397-413.
3. Chen CS, Weng SC, Tseng PH, Lin HP, Chen CS. Histone acetylation- independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J Biol Chem 2005;280:38879-87.
4. Weterings E, van Gent DC. The mechanism of nonhomologous end-joining: a synopsis of synapsis. DNA Repair (Amst) 2004;3:1425-35.
5. Chou CH, Wang J, Knuth MW, Reeves WH. Role of a major autoepitope in forming the DNA binding site of the p70 (Ku) antigen. J Exp Med 1992;175:1677-84.
6. Wang J, Dong X, Myung K, Hendrickson EA, Reeves WH. Identification of two domains of the p70 Ku protein mediating dimerization with p80 and DNA binding. J Biol Chem 1998;273:842-8.
7. Wang J, Dong X, Reeves WH. A model for Ku heterodimer assembly and interaction with DNA. Implications for the function of Ku antigen. J Biol Chem 1998;273:31068-74.
8. Wu X, Lieber MR. Protein-protein and protein-DNA interaction regions within the DNA end-binding protein Ku70-86. Mol Cell Biol 1996;16:5186-93.
9. Sawada M, Hayes P, Matsuyam S. Cytoprotective membrane-permeable peptides designed from the Bax-binding domain of Ku70. Nat Cell Biol 2003;5:352-7.
10. Sawada M, Sun W, Hayes P, Leskov K, Boothman DA, Matsuyama S. Ku70 suppresses the apoptotic translocation of Bax to mitochondria. Nat Cell Biol 2003;5:320-9.
11. Nothwehr SF, Martinou JC. A retention factor keeps death at bay. Nat Cell Biol 2003;5:281-3.
12. Cohen HY, Lavu S, Bitterman KJ, et al. Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol Cell 2004;13:627-38.
13. Cohen HY, Miller C, Bitterman KJ, et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 2004;305:390-2. 14. Subramanian C, Opipari AW, Jr., Bian X, Castle VP,
14. Kwok RP. Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2005;102:4842-7.
15. Lu Q, Wang DS, Chen CS, Hu YD, Chen CS. Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem 2005;48:5530-5.
16. 2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem 2004;47:467-74.
17. Kulp S K, Chen CS, Wang DS, Chen CY, Chen CS. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer. Clin Cancer Res 2006;12:5199-206.
18. Kim JH, Shin JH, Kim IH. Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor. Int J Radiat Oncol Biol Phys 2004;59:1174-80.
19. Fiser A, Do RK, Sali A. Modeling of loops in protein structures. Protein Sci 2000;9:1753-73.
20. Singh UC, Kollman PA. An approach to computing electrostatic charges for molecules. J Comp Chem 1984;5:129-45.
21. Morris GM, Goodsell DS, Halliday RS, et al. Automated docking using a Lamarckian genetic algorithm and an empirical free energy function. J Comp Chem 1998;19:1639-62.
22. Walker JR, Corpina RA, Goldberg J. Structure of the Ku heterodimer bound to DNA and its implications for double-strand break repair. Nature 2001;412:607-14.
23. Isaacs WB, Carter BS, Ewing CM. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 1991;51:4716-20.
24. Yin MB, Rustum YM. Comparative DNA strand breakage induced by FUra and FdUrd in human ileocecal adenocarcinoma (HCT-8) cells: relevance to cell growth inhibition. Cancer Commun 1991;3:45-51.
25. Sampath D, Rao VA, Plunkett W. Mechanisms of apoptosis induction by nucleoside analogs. Oncogene 2003;22:9063-74.
26. Rochester MA, Riedemann J, Hellawell GO, Brewster SF, Macaulay VM. Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer. Cancer Gene Ther 2005;12:90-100.
27. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 2003;63:7291-300.
28. Munshi A, Kurland JF, Nishikawa T, et al. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res 2005;11:4912-22.
29. Banath JP, Olive PL. Expression of phosphorylated histone H2AX as a surrogate of cell killing by drugs that create DNA double-strand breaks. Cancer Res 2003;63:4347-50.
30. Zhang Y, Adachi M, Zou H, Hareyama M, Imai K, Shinomura Y. Histone deacetylase inhibitors enhance phosphorylation of histone H2AX after ionizing radiation. Int J Radiat Oncol Biol Phys 2006;65:859-66.
31. Hasan S, Stucki M, Hassa PO, et al. Regulation of human flapen donuclease-1 activity by acetylation through the transcriptional coactivator p300. Mol Cell 2001;7:1221-31.
32. Caillaud A, Prakash A, Smith E, et al. Acetylation of interferon regulatory factor-7 by p300/CREB-binding protein (CBP)-associated factor (PCAF) impairs its DNA binding. J Biol Chem 2002;277:49417-21.
33. Kurz EU, Wilson SE, Leader KB, et al. The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase IIα expression and confers hypersensitivity to etoposide in human leukemic cell lines. Mol Cancer Ther 2001;1:121-31.
34. Shack S, Miller A, Liu L, Prasanna P, Thibault A, Samid D. Vulnerability of multidrug-resistant tumor cells to the aromatic fatty acids phenylacetate and phenylbutyrate. Clin Cancer Res 1996;2:865-72.
35. Pienta KJ, Redman B, Hussain M, et al. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 1994;12:2005-12.
36. Small EJ, Srinivas S, Egan B, McMillan A, Rearden TP. Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer. J Clin Oncol 1996;14:1617-25.
37. Haas NB, Manola J, Hudes G, Citrin DL, Kies MS, Davis TE. Phase II pilot study of combined chemohormonal therapy with doxorubicin and estramustine in metastatic prostate cancer. Am J Clin Oncol 2000;23:589-92.
38. Smith DC, Chay CH, Dunn RL, et al. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma. Cancer 2003;98:269-76.
39. Borden LS, Jr., Clark PE, Lovato J, et al. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer. Cancer 2006;107:1093-100.
40. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20.
41. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
42. Fiedler W, Tchen N, Bloch J, et al. A study from the EORTC new drug development group: open label phase II study of sabarubicin (MEN-10755) in patients with progressive hormone refractory prostate cancer. Eur J Cancer 2006;42:200-4.